Table 1 Demographics characteristics of case and control
From: Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study
Surfactant (n = 7, 0.33%) | Control (n = 14, 0.66%) | P value | |
|---|---|---|---|
Age, mean (SD) | 66.14 (4.33) | 60.85 (10.79) | 0.232 |
Gender male, n (%) | 6 (85.7%) | 11(78.6%) | 0.873 |
BMI, mean (SD) | 28.60 (4.54) | 28.71 (4.49) | 0.958 |
SAPSII, mean (SD) | 49.14 (12.30) | 43.92 (15.42) | 0.447 |
Cardiopathy, n (%) | 5 (71.4%) | 4 (28.5%) | 0.124 |
Diabetes, n (%) | 1 (14.3%) | 2 (14.3%) | 0.247 |
Immunodepression, n (%) | 0 (0%) | 2 (14.3%) | 0.530 |
Obesity, n (%) | 2 (28.6%) | 3 (21.4%) | 0.998 |
Pneumopathy, n (%) | 1 (14.3%) | 0 (0%) | 0.335 |